Healthcare provider profile · identity verified

Sasikala Royyuru, MD

Family Practice · BLOOMINGTON, IL · NPI 1982800876

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	443	122
Levothyroxine Sodium	Levothyroxine Sodium	329	77
Amlodipine Besylate	Amlodipine Besylate	170	52
Hydrochlorothiazide	Hydrochlorothiazide	163	46
Simvastatin	Simvastatin	126	28
Rosuvastatin Calcium	Rosuvastatin Calcium	118	36
Duloxetine Hcl	Duloxetine Hcl	116	31
Losartan Potassium	Losartan Potassium	116	34
Lisinopril	Lisinopril	114	33
Omeprazole	Omeprazole	113	33
Gabapentin	Gabapentin	103	29
Metoprolol Succinate	Metoprolol Succinate	102	25
Metformin Hcl Er	Metformin Hcl	99	26
Sertraline Hcl	Sertraline Hcl	94	29
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	86	20
Furosemide	Furosemide	84	18
Montelukast Sodium	Montelukast Sodium	83	22
Carvedilol	Carvedilol	81	15
Citalopram Hbr	Citalopram Hydrobromide	80	29
Trazodone Hcl	Trazodone Hcl	80	20
Tramadol Hcl	Tramadol Hcl	57	15
Glipizide Er	Glipizide	56	13
Ibandronate Sodium	Ibandronate Sodium	56	18
Atenolol	Atenolol	52	17
Fluticasone Propionate	Fluticasone Propionate	51	25
Pantoprazole Sodium	Pantoprazole Sodium	50	14
Alendronate Sodium	Alendronate Sodium	45	14
Potassium Chloride	Potassium Chloride	45	12
Metformin Hcl	Metformin Hcl	44	13
Ozempic	Semaglutide	43	suppressed
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	41	12
Eliquis	Apixaban	37	suppressed
Metoprolol Tartrate	Metoprolol Tartrate	37	13
Meloxicam	Meloxicam	34	15
Methylprednisolone	Methylprednisolone	34	30
Pravastatin Sodium	Pravastatin Sodium	34	12
Bupropion Xl	Bupropion Hcl	33	suppressed
Spironolactone	Spironolactone	33	suppressed
Alprazolam	Alprazolam	31	21
Cephalexin	Cephalexin	31	25
Albuterol Sulfate Hfa	Albuterol Sulfate	29	25
Escitalopram Oxalate	Escitalopram Oxalate	29	suppressed
Januvia	Sitagliptin Phosphate	28	suppressed
Ropinirole Hcl	Ropinirole Hcl	28	11
Doxepin Hcl	Doxepin Hcl	27	suppressed
Famotidine	Famotidine	27	suppressed
Glimepiride	Glimepiride	27	suppressed
Baclofen	Baclofen	26	11
Oxybutynin Chloride Er	Oxybutynin Chloride	24	suppressed
Allopurinol	Allopurinol	22	suppressed
Celecoxib	Celecoxib	22	12
Estradiol	Estradiol	22	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	22	suppressed
Pramipexole Dihydrochloride	Pramipexole Di-Hcl	22	suppressed
Tamsulosin Hcl	Tamsulosin Hcl	22	suppressed
Hydralazine Hcl	Hydralazine Hcl	21	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	21	suppressed
Mounjaro	Tirzepatide	20	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	20	suppressed
Diazepam	Diazepam	19	suppressed
Doxycycline Monohydrate	Doxycycline Monohydrate	19	15
Fluoxetine Hcl	Fluoxetine Hcl	19	suppressed
Xarelto	Rivaroxaban	19	suppressed
Paroxetine Hcl	Paroxetine Hcl	18	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	18	suppressed
Sucralfate	Sucralfate	18	suppressed
Zolpidem Tartrate	Zolpidem Tartrate	18	suppressed
Pregabalin	Pregabalin	17	suppressed
Valsartan	Valsartan	17	suppressed
Arnuity Ellipta	Fluticasone Furoate	16	suppressed
Clopidogrel	Clopidogrel Bisulfate	16	suppressed
Enalapril Maleate	Enalapril Maleate	15	suppressed
Lorazepam	Lorazepam	15	suppressed
Glipizide	Glipizide	14	suppressed
Meclizine Hcl	Meclizine Hcl	14	suppressed
Tizanidine Hcl	Tizanidine Hcl	14	suppressed
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	13	suppressed
Ibuprofen	Ibuprofen	13	suppressed
Nucynta	Tapentadol Hcl	13	suppressed
Rivastigmine	Rivastigmine	13	suppressed
Valsartan-Hydrochlorothiazide	Valsartan/Hydrochlorothiazide	13	suppressed
Basaglar Kwikpen U-100	Insulin Glargine,hum.Rec.Anlog	12	suppressed
Buspirone Hcl	Buspirone Hcl	12	suppressed
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	12	suppressed
Qvar Redihaler	Beclomethasone Dipropionate	12	suppressed
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	11	suppressed
Ondansetron Hcl	Ondansetron Hcl	11	suppressed
Topiramate	Topiramate	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error